Webinar: Turning Precision Medicine into Action in Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.

Case Study: How Cerba Research Helped Advance a Phase IIB Study in the Middle of a Pandemic and Brexit

How To Improve the Patients Experience in IO Clinical Trials – with the Gustave Roussy Institute

Webinar: The Advantages and Versatility of Flow Cytometry in Clinical Development

It is clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flow Cytometry, which allows for precise analysis of liquid samples, but not only that.

Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading technique of analysis for the development of innovative treatments, our experts will share their knowledge and experience.

Speakers

Nithianandan Selliah, Ph.D. – Global Head of Flow Cytometry at Cerba Research

Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion of Flow cytometry in clinical trials and takes on new challenges to build the best Flow cytometry service for the clients. He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.

Ishita Modi – Director, Scientific Customer Solutions at Cerba Research

A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to starting her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State certified Medical Technologist and also certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.

Tech Transfer IFE Reflex Assay China

A Biotech Company in China required our scientific expertise for the Tech Transfer of IFE Reflex Assay on a clinical trial in the Oncology field (Relapsed or Refractory Multiple Myeloma). Cerba Research was not the Biotech’s central or specialty laboratory on the study but brought in for our expertise on the tech transfer.

Download the case study to read more.

SARS-CoV-2 ELISpot: a New Test in the COVID-19 Diagnostic and Vaccine Arsenal

What is an ELISpot Assay?

The assay consists of measuring the specific cellular response against more than 250 peptides of the SARS-CoV-2 Spike (S) and Nucleocapsid (N) proteins by quantifying the number of interferon-producing T cells. The lymphocytes of ill or vaccinated patients are isolated and then brought into contact with the virus antigens. After 20 hours of incubation, the production of interferon is measured. A positive assay allows differentiating the immunity related to infection with the virus (testing positive for anti-SARS-CoV-2 S-protein and N-protein antibodies) from the immunity related to vaccination (testing positive only for anti-SARS-CoV-2 S-protein antibodies).

Download the flyer to learn more.

Conducting Clinical Trials During COVID-19: Lessons for the Next Pandemic

The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola, and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine, and genetic studies.

To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.

Register for this webinar to learn the answers to these questions:

  • Did we succeed, how fast did we adapt, and are we ready to face a new pandemic crisis in the future?
  • How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?

Webinar: Leveraging Medical Laboratory Data for Patient Recruitment

Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow

Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.

Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba Research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhance access to data.  The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.

Watch the recording of our webinar held in April 2021 to learn more!

Pediatric Phase I/II Clinical Trial on Mucopolysaccharidosis type III (MPSIIIA)

Lab support for a global pediatric trial for the rare genetic neurodegenerative disorder, Mucopolysaccharidosis type III. Cerba Research provided safety testing, sample management, and specialized testing in our histology lab. Read the case study to discover more details.

Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)

Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.